Fedratinib

SAN DIEGO — Treatment with fedratinib led to “superior” spleen volume reduction and symptom response rates in patients with myelofibrosis previously treated with ruxolitinib, according to data presented at ASH Annual Meeting and Exposition.

In this video, Jeanne M. Palmer, MD, hematologist and oncologist at the Mayo Clinic, discussed recent FDA approvals in the field.